Litcius/Paper detail

Acquired Tertiary MET Resistance (MET D1228N and a Novel LSM8-MET Fusion) to Selpercatinib and Capmatinib in a Patient With KIF5B-RET–positive NSCLC With Secondary MET Amplification as Initial Resistance to Selpercatinib

Viola W. Zhu, Shannon Zhang, Jian Zhang, Jeffrey Swensen, Joanne Xiu, Sai‐Hong Ignatius Ou

2021Journal of Thoracic Oncology22 citationsDOIOpen Access PDF

Topics & Concepts

MedicineOncologynon-small cell lung cancer (NSCLC)Internal medicineCancer researchLungA549 cellLung Cancer Treatments and MutationsColorectal Cancer Treatments and StudiesCholangiocarcinoma and Gallbladder Cancer Studies
Acquired Tertiary MET Resistance (MET D1228N and a Novel LSM8-MET Fusion) to Selpercatinib and Capmatinib in a Patient With KIF5B-RET–positive NSCLC With Secondary MET Amplification as Initial Resistance to Selpercatinib | Litcius